Equine Antisera for Anthrax Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anthrax vaccines have limited availability, require multiple doses, and can cause adverse reactions, while antibiotic treatments for anthrax infection are ineffective against resistant strains and require early administration, necessitating alternative prevention and treatment methods.
Innovation Solution
Development of compositions and methods using isolated or purified equine antisera against Bacillus anthracis, specifically antibodies against protective antigen (PA), lethal factor (LF), and edema factor (EF), which can be administered to individuals at risk or infected with anthrax, optionally in conjunction with antimicrobial agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anthrax vaccines are used, then prevention of anthrax infection is achieved, but availability is limited and multiple doses are required
Solution Approach 1:
The patent extracts the protective function from the complex vaccine system and delivers it through a single injection of equine antisera containing pre-formed antibodies against anthrax toxins, eliminating the need for multiple vaccine doses while maintaining prevention effectiveness
Solution Approach 2:
The patent uses equine antisera as an intermediary substance that carries pre-formed antibodies against anthrax toxins, allowing the immune protection function to be transferred from the equine donor to the human recipient without requiring the human to produce their own antibodies through multiple vaccine doses
2Reliability
If current anthrax vaccines are used, then prevention of anthrax infection is achieved, but adverse reactions occur at injection sites
Solution Approach 1:
The patent uses a single-dose equine antiserum preparation that provides immediate protection without the need for repeated vaccinations, thereby avoiding cumulative adverse reactions that occur with multiple vaccine doses while maintaining effective prevention
3Reliability
If antibiotics are used to treat anthrax infection, then infection treatment is achieved, but resistant strains develop and treatment must be administered early
Solution Approach 1:
The patent provides preliminary protection by administering equine antisera containing pre-formed antibodies before infection occurs or at the time of exposure, eliminating the need to wait for antibiotic treatment to take effect and providing immediate neutralization of toxins
Solution Approach 2:
The patent uses equine antisera as an intermediary therapeutic agent that provides immediate passive immunity against anthrax toxins, bridging the time gap between exposure and effective treatment by delivering pre-formed antibodies that act instantly without requiring early antibiotic administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The equine antisera compositions effectively inhibit or prevent anthrax infection by neutralizing the exotoxin complex, providing a viable alternative for prevention and treatment, including against antibiotic-resistant strains.
Implementation Method 1
The equine antisera compositions effectively inhibit or prevent anthrax infection by neutralizing the exotoxin complex
Data Source
AI summary
Disclosed are compositions and methods for treating a subject infected with Bacillus anthracis or at risk for infection with B. anthracis. The compositions include and the methods utilize isolated or purified equine antisera against B. anthracis.